Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This randomized, controlled trial compares the anti-thrombotic effect of cangrelor and
ticagrelor on platelet activity in patients with acute ST-elevation myocardial infarction.
Patients will receive either prehospital ticagrelor (180 mg - crushed) or in-hospital
cangrelor (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two
hours) followed by 180 mg ticagrelor.
The primary study end-point is platelet reactivity at sheath insertion, at the end of the PCI
procedure (before sheath removal) and two hours after PCI is initiated. The secondary
end-point is the proportion of patients with inappropriate or harmful P2Y12 administration.